Eli Lilly and Co (LLY) Stake Decreased by Grassi Investment Management
Grassi Investment Management decreased its holdings in Eli Lilly and Co (NYSE:LLY) by 0.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,290 shares of the company’s stock after selling 742 shares during the quarter. Grassi Investment Management’s holdings in Eli Lilly and were worth $7,626,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. Pathstone Family Office LLC lifted its position in Eli Lilly and by 100.0% during the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after acquiring an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. acquired a new stake in Eli Lilly and during the 2nd quarter worth about $494,000. Acrospire Investment Management LLC lifted its position in Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new stake in Eli Lilly and during the 2nd quarter worth about $128,000. Finally, San Francisco Sentry Investment Group CA acquired a new stake in Eli Lilly and during the 2nd quarter worth about $129,000. 76.31% of the stock is owned by hedge funds and other institutional investors.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the completion of the sale, the senior vice president now directly owns 124,522 shares in the company, valued at approximately $10,766,172.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 251,088 shares of company stock valued at $22,041,236. 0.20% of the stock is owned by company insiders.
Shares of Eli Lilly and Co (LLY) traded up $0.04 during trading on Wednesday, hitting $86.10. The company had a trading volume of 1,674,425 shares, compared to its average volume of 2,756,557. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 1 year low of $74.00 and a 1 year high of $89.09. The stock has a market cap of $94,800.00, a price-to-earnings ratio of 41.00, a PEG ratio of 1.62 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the previous year, the business earned $0.88 EPS. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. sell-side analysts anticipate that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.61%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is currently 99.05%.
A number of analysts have commented on the company. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and lifted their price target for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 12th. Morgan Stanley boosted their price objective on Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a report on Tuesday, November 21st. Finally, Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and an average target price of $92.14.
WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/eli-lilly-and-co-lly-stake-decreased-by-grassi-investment-management/1801752.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with Analyst Ratings Network's FREE daily email newsletter.